Optimum treatment for young women with breast cancer needs to be determined

BMJ 2000; 321 doi: 10.1136/bmj.321.7252.53 (Published 1 July 2000)
Cite this as: BMJ 2000;321:53.1

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Richard Sainsbury, consultant surgeon (jrcs@compuserve.com),
  2. Bob Haward, professor of cancer studies
  1. Huddersfield Royal Infirmary, Huddersfield HD3 3EA
  2. University of Leeds, Leeds LS2 9JT

    EDITOR—The paper by Kroman et al on factors influencing the effect of age on prognosis in breast cancer has important implications for service delivery,1 increased amounts of chemotherapy being required for young women. The authors imply that only women at high risk received adjuvant chemotherapy. In all, 36.3% of their 867 patients under 35 were in the low risk group, an excess mortality being associated with not receiving chemotherapy.

    We used the Yorkshire Cancer …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL